A study on the synergistic antibacterial effects of CTAB-capped silver nanoparticles and antibiotics

Date

2024-1-24

Author

Akköse, Asu Pelin

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

167
views

371
downloads

Cite This

Antibacterial agents are used to treat bacterial infections. Although antibiotics are the most common choice to treat bacterial infections, over time, bacteria can develop resistance to them, posing a significant risk to public safety. Hence, attempts have been made to replace antibiotics or reduce their dosage. Silver nanoparticles (AgNPs) and their combinations with antibiotics in clinical use have shown promise due to their antibacterial activity. In this study, CTAB-capped AgNPs with an average size of 28.8 nm was synthesized and tested for their individual antibacterial activities. The synergy tests were conducted where AgNPs were combined with the antibiotics, including ciprofloxacin, vancomycin, amoxicillin, rifampicin and linezolid. The antibiotic-AgNPs combinations were tested against Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 25923), Pseudomonas aeruginosa (ATCC 9027), Bacillus subtilis (ATCC 6633) and Streptococcus sanguinis (ATCC 29677). The results showed that AgNPs have a synergistic relation with amoxicillin against E. coli and linezolid against S. sanguinis but not with vancomycin against S. aureus and rifampicin against B. subtilis. However, the presence of AgNPs reduced the required amount of antibiotics to inhibit the studied bacteria. It was found that AgNPs, which were capped with CTAB, did not exhibit any synergistic or indifferent relationship with ciprofloxacin against E. coli and P. aeruginosa, nor with rifampicin against S. aureus. However, the presence of these AgNPs reduced the amount of rifampicin required to fight B. subtilis and vancomycin required to fight S. aureus, without enhancing their individual antibacterial activity. Furthermore, when combined with amoxicillin and linezolid, these AgNPs reduced the dosage required to fight E. coli and S. sanguinis, respectively, while also synergistically enhancing their antibacterial activity. Therefore, it was concluded that CTAB-capped AgNPs could be used in combination with amoxicillin against E. coli, linezolid against S. sanguinis, rifampicin against B. subtilis, as well as vancomycin against S. aureus to fight with antibiotic resistance.

Subject Keywords

Silver nanoparticles, Antibiotics, Synergistic effect, Antibacterial effect

URI

https://hdl.handle.net/11511/108789

Collections

Graduate School of Natural and Applied Sciences, Thesis